Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of intravenous efgartigimod in generalized myasthenia gravis
jRCT2080225049Phase 3Completed
- Sponsor
- argenx
- Start
- Feb 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Primary endpoint: Safety and tolerability. Started Feb 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2080225049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225049.